Stephen Poor

Stephen Poor

Company: Novartis

Job title: Global Program Clinical Head


Overcoming the Bio-Incompatibility of Chemical Material Used for Sustained Drug Release in the Retina 8:30 am

Exploring slow eluding polymers that can be used for the implant that are bio-compatible with the eye and the drug inside the reservoir Biodegradable implants; what are the best properties for implant technology and drug and how do they work together to avoid proprietary inflammation? Examining the prolonged delivery of biologics using a polymer-based sustained-release…Read more

day: Conference Day One

Advances with Subretinal Delivery Route 10:30 am

Subretinal surgery has been around as a route of delivering drugs into the eye. An invasive yet effective mechanism of reaching the retina. Unfortunately, it remains an unrealistic method when delivering drugs every once every month. With elderly patients, there are several other health concerns to consider. Frequent ocular surgery could result in a higher…Read more

day: Pre-Conference Workshop Day - WORKSHOP C

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.